A5082053412- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Hematopoietic Stem Cell Transplantation
- Cutaneous lymphoproliferative disorders research
- Sarcoma Diagnosis and Treatment
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- Genetic factors in colorectal cancer
- Acute Lymphoblastic Leukemia research
- Cardiac tumors and thrombi
- Testicular diseases and treatments
- Toxin Mechanisms and Immunotoxins
- Neutropenia and Cancer Infections
- Glutathione Transferases and Polymorphisms
- Cancer Genomics and Diagnostics
- Vascular Tumors and Angiosarcomas
- Venous Thromboembolism Diagnosis and Management
- Transplantation: Methods and Outcomes
- Gut microbiota and health
- RNA modifications and cancer
Oulu University Hospital
2016-2025
University of Oulu
2011-2025
Kuopio University Hospital
2023
Northern Ostrobothnia Hospital District
2021
Gut microbiome–derived nanoparticles, known as bacterial extracellular vesicles (bEVs), have garnered interest promising tools for studying the link between gut microbiome and human health. The diverse composition of bEVs, including their proteins, mRNAs, metabolites, lipids, makes them useful investigating diseases such cancer. However, conventional approaches alone may not be accurate in deciphering host–gut communication. In clinical research, there is a gap knowledge on role bEVs solid...
ABSTRACT Mantle cell lymphoma is a rare type of B‐cell lymphoma, which considered incurable yet treatable. In recent years, the treatment options mantle have multiplied, and focus expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development hindered by high costs targeted therapies. To provide baseline for future assessment benefits new emerging MCL treatments, we established predictive simulated model lifetime trajectories based on retrospective...
ABSTRACT Purpose The prognosis of relapsed primary central nervous system lymphoma remains a concern. This study aimed to compare the effects various patient‐ and disease‐related factors on (PCNSL). Methods We retrospectively collected real‐world data from eight Finnish hospitals 198 patients diagnosed with PCNSL between 2003 2020. Characteristics were available. At total 63 relapses included after excluding seven isolated ocular relapses. Results median progression‐free survival relapse was...
Abstract Hodgkin’s lymphoma (HL) is a lymphoid malignancy with an emphasized incidence in developed countries. This study aimed to assess the changes epidemiology of HL Finland at population level by utilizing data from six nationwide healthcare registries. A total 2912 patients HL, diagnosed and treated between 2000 2019 were matched controls divided into younger (<50 years) older cohorts (≥50 for analysis. slightly increasing trend per age group was observed. For patients, mean...
Abstract Relapsed or refractory mantle cell lymphoma (R/R MCL) remains difficult to treat, with outcomes dependent on the treatment regimen and remission duration after first‐line therapy. Several non‐chemotherapeutic regimens are under evaluation in R/R, but few studies report long‐term outcomes. In this study, we present of 50 patients treated ibrutinib, lenalidomide, rituximab (IR2) Nordic Lymphoma Group MCL6 Philemon phase 2 trial. Survival were compared a matched cohort from Swedish MCL...
Abstract Background Rituximab‐based combinations are the standard of care in diffuse large B‐cell lymphoma (DLBCL) and follicular (FL). Despite being on market for over 20 years, some adverse effects associated with use rituximab not well known. Drug‐induced interstitial pneumonitis (DIP) is a potentially fatal complication treatment. Granulocyte colony‐stimulating factors (G‐CSF) supportive agents commonly used to prevent neutropenic infections. G‐CSF reported have pulmonary toxicity, but...
Background Plerixafor is used in combination with granulocyte–colony‐stimulating factor to enhance the mobilization of hematopoietic stem cells. Limited data are available regard effects plerixafor on posttransplant outcomes chemomobilized patients who appear mobilize poorly. Study Design and Methods Eighty‐nine non‐Hodgkin's lymphoma ( NHL ) were included this retrospective study. Thirty‐three had received preemptively (plerixafor group) 56 served as controls. Posttransplantation including...
Abstract Bulky and residual tumor are considered to increase the risk of relapse in diffuse large B‐cell lymphoma (DLBCL) patients. Radiotherapy is conventionally used reduce risk, but evidence controversial. We performed a retrospective analysis evaluate significance bulky treated with or without radiotherapy DLBCL analyzed 312 patients from 2010‐2017 Oulu University Hospital. A was detected 123 55 these (44.3%) received consolidative radiation therapy (RT) tumor. Residual meeting required...
We report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland.Finnish Cancer Registry data by histological diagnosis tumor location (2007-2017) for cases with diffuse large B-cell lymphoma.During 2007-2017, 392 new PCNSL were reported (195 males, 197 females). The average age-adjusted was 0.68/100,000 person-years. Incidence males 0.74/100,000 females 0.63/100,000, respectively. highest, 2.93/100,000, among people aged...
Early lymphocyte recovery as manifested by an absolute count at d+15 (ALC-15) ≥ 0.5 × 109/L after autologous hematopoietic stem cell transplantation (AHCT) has been associated with a better outcome. This prospective multicenter study aimed to clarify factors ALC-15 AHCT among 178 patients non-Hodgkin lymphoma. The mobilization capacity, peak blood CD34+ numbers > 45 106/L correlated higher levels (p = 0.020). In addition, the amount of CD3+CD4+ T cells 31.8 106/kg in infused graft...
Although oxidative stress plays an important role in the biology of solid malignant tumors, little is known about hematological malignancies. In this study, we evaluated immunohistochemical expression and clinical correlations markers several essential antioxidant enzymes B-cell lymphomas. Paraffin-embedded diagnostic tissue samples from 18 diffuse large lymphomas (DLBCL), follicular (FL), 19 Hodgkin (HL), 7 chronic lymphocytic leukemias (CLL), mantle cell (MCL) mucosa-associated lymphoid...
Summary Mantle cell lymphoma (MCL) is a rare peripheral B‐cell characterised by eventual relapse and progression towards more aggressive disease biology. With the introduction of rituximab‐ cytarabine‐based immunochemotherapy regimens, prognosis has changed dramatically over last two decades. To assess real‐world survival patients with MCL, we used population‐based cohort 564 MCL who were diagnosed treated between 2000 2020. Patient data collected from seven Finnish treatment centres one...
Primary central nervous system lymphoma (PCNSL) is a rare brain tumour with dismal prognosis. Several phase II studies high-dose methotrexate-based regimens have shown promising early results, but in all hospital-based data published so far, the disease outcome poor.We performed retrospective analysis to evaluate long-term results of Nordic type Bonn chemotherapy regimen PCNSL patients. The study included 54 patients newly diagnosed who received curative intent as their first-line...
Autologous stem cell transplantation (auto-SCT) is an established treatment option in patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect of infused blood graft cellular composition on post-transplant outcome was analyzed 129 NHL patients. Higher CD34+ content (>2.5 × 106/kg) correlated better progression-free survival (PFS) (p=.009) and overall (OS) (p=.004). CD34+CD133+CD38– counts (>0.08 were also linked PFS (p=.03) OS (p=.004), these benefits...
Limited data is available about the factors affecting early immune recovery or its clinical significance after autologous stem cell transplantation (auto-SCT). We prospectively analyzed and outcome among 72 non-Hodgkin lymphoma (NHL) patients. Absolute lymphocyte count 15 d auto-SCT (ALC-15) ≥ 0.5 × 109/L was associated with use of plerixafor (p = 0.004), number CD34+ cells 0.015), CD38− 0.005) in grafts. ALC-15 improved overall survival 0.021). In patients aggressive histology, beneficial...
Abstract Although overall survival in diffuse large B cell lymphomas (DLBCL) has improved, central nervous system (CNS) relapse is still a fatal complication of DLBCL. For this reason, CNS prophylaxis recommended for patients at high risk disease. However, no consensus exists on definition high-risk patient and optimal prophylaxis. Systemic high-dose methotrexate combination with R-CHOP been suggested as potential prophylactic method, since penetrates the blood-brain barrier achieves...
Summary Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many comparable treatment options available for FL. When selecting optimal therapy it important to consider possible late effects of as well survival. Secondary haematological malignancy (SHM) a severe effect treatments, but incidence SHMs still largely unknown. The goal present study was determine and how therapeutic decisions interfere with this risk. included 1028 FL patients median follow‐up time...
Abstract The application of positron emission tomography (PET)‐computed (CT) in treatment response evaluation has increased diffuse large B‐cell lymphoma (DLBCL), although its predictive value is controversial. We retrospectively analyzed the rate false‐positive PET‐CTs performed as interim ( n = 94) and end‐of‐treatment 8) assessments among 102 DLBCL patients treated during 2010–2017 at Oulu University Hospital. In PET‐CT Deauville score ≥4 was regarded positive. A biopsy on 35 patients,...
Abstract Background There are few reports of clinical practice treatment patterns and efficacy in mantle cell lymphoma (MCL). Materials Methods We retrospectively studied a large, multicenter, cohort patients with MCL diagnosed between 2000 2020 eight institutions. Results 536 were registered (73% male, median 70 years). Front‐line was based on high‐dose cytarabine, bendamustine, anthracyclines 42%, 12%, 15%, respectively. The PFS for all 45 months; 68, 34, 30 months those who received...
The optimal follow-up protocol for primary central nervous system lymphoma (PCNSL) is unclear. This the first study to evaluate benefit of structured imaging PCNSL with respect timing relapse.
BACKGROUND Autologous stem cell transplantation is an established treatment option for patients with multiple myeloma (MM) or non‐Hodgkinʼs lymphoma (NHL). STUDY DESIGN AND METHODS In this prospective multicenter study, 147 MM were compared 136 NHL regarding the mobilization and apheresis of blood CD34+ cells, cellular composition infused grafts, posttransplant recovery, outcome. RESULTS Multiple mobilized cells more effectively (6.3 × 10 6 /kg vs. 3.9 /kg, p = 0.001). The proportion poor...